CEL-SCI (NYSE:CVM) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of CEL-SCI (NYSE:CVM) in a report released on Saturday. The brokerage set a “sell” rating on the stock.

CEL-SCI Stock Performance

Shares of NYSE CVM opened at $0.39 on Friday. The firm has a market capitalization of $28.83 million, a price-to-earnings ratio of -0.76 and a beta of 0.65. CEL-SCI has a one year low of $0.36 and a one year high of $3.08. The business has a fifty day simple moving average of $0.53 and a 200 day simple moving average of $0.86. The company has a current ratio of 1.31, a quick ratio of 1.09 and a debt-to-equity ratio of 0.62.

Institutional Investors Weigh In On CEL-SCI

Several large investors have recently modified their holdings of CVM. Plotkin Financial Advisors LLC acquired a new stake in CEL-SCI in the 3rd quarter valued at about $98,000. Geode Capital Management LLC boosted its position in CEL-SCI by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock valued at $650,000 after buying an additional 53,879 shares during the last quarter. Calton & Associates Inc. acquired a new stake in shares of CEL-SCI in the 3rd quarter valued at $50,000. Finally, Renaissance Technologies LLC raised its position in shares of CEL-SCI by 29.9% during the second quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock worth $202,000 after acquiring an additional 40,000 shares during the last quarter. 12.08% of the stock is currently owned by institutional investors.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.